Analysis of the Amine Submetabolome Using Novel Isotope-Coded Pyrylium Salt Derivatization and LC-MS: Herbs and Cancer Tissues as Cases.
- Liu L et al (2022).
- Anal Chem.
- PubMed:
- 36473140
This article discusses the historical relevance of the approval of cannabidiol (CBD) for epilepsy treatment. Unlike its related compound, marijuana's Δ9-tetrahydrocannabinol, CBD does not have any euphorigenic or withdrawal effects at anticonvulsant doses. CBD also has anti-inflammatory properties. Though CBD's anticonvulsant properties were suggested in a few studies in rodent seizure models, social and regulatory pressures kept it from being clinically implemented. However, CBD was approved for the orphan disease Dravet syndrome in 2018 after its efficacy was established in randomized, placebo-controlled trials in children. The article suggests that CBD's approval is a key driver of a new discovery strategy for epilepsy treatment in the 21st century.